Abstract
Herpes simplex virus infections are the cause of significant morbidity, and currently used therapeutics are largely based on modified nucleoside analogs that inhibit viral DNA polymerase function. To target this disease in a new way, we have identified and optimized selective thiazolylphenyl-containing inhibitors of the herpes simplex virus (HSV) helicase-primase enzyme. The most potent compounds inhibited the helicase, the primase and the DNA-dependent ATPase activities of the enzyme with IC50 (50% inhibitory concentration) values less than 100 nM. Inhibition of the enzymatic activities was through stabilization of the interaction between the helicase-primase and DNA substrates, preventing the progression through helicase or primase catalytic cycles. Helicase-primase inhibitors also prevented viral replication as demonstrated in viral growth assays. One compound, BILS 179 BS, displayed an EC50 (effective concentration inhibiting viral growth by 50%) of 27 nM against viral growth with a selectivity index greater than 2,000. Antiviral activity was also demonstrated for multiple strains of HSV, including strains resistant to nucleoside-based therapies. Most importantly, BILS 179 BS was orally active against HSV infections in murine models of HSV-1 and HSV-2 disease and more effective than acyclovir when the treatment frequency per day was reduced or when initiation of treatment was delayed up to 65 hours after infection. These studies validate the use of helicase-primase inhibitors for the treatment of acute herpesvirus infections and provide new lead compounds for optimization and design of superior anti-HSV agents.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Whitley, R.J. Herpes simplex viruses. in Fields Virology (eds. Fields, B.N., Knipe, D.M. & Howley,P.M.) 2297–2342 (Raven, New York, 1995).
Perry, C.M. & Faulds, D. Valacyclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in herpesvirus infections. Drugs 52, 754–772 (1996).
Vere Hodge, R.A. Famciclovir and penciclovir. The mode of action of famciclovir including its conversion to penciclovir. Antiviral Chem. Chemother. 4, 67–84 (1993).
Reardon, J.E. & Spector, T. Acyclovir: mechanism of action and potentiation by ribonucleotide reductase inhibitors. in Advances in Pharmacology (ed. Augusta, T.) 1–27 (Academic, New York, 1991).
Kimberlin, D.W. et al. Antiviral resistance in clinical practice. Antiviral Res. 26, 423–438 (1995).
Challberg, M. Herpesvirus DNA replication. in DNA Replication in Eukaryotic Cells (ed. DePamphilis, M.L.) 721–750 (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1996).
Lehman, I.R. & Boehmer, P.E. Replication of herpes simplex virus DNA. J. Biol. Chem. 274, 28059–28062 (1999).
Matthews, J.T., Terry, B.J. & Field, A.K. The structure and function of the HSV DNA replication proteins: defining novel antiviral targets. Antiviral Res. 20, 89–114 (1993).
Crute, J.J. & Lehman, I.R. Herpes simplex virus helicase-primase. Physical and catalytic properties. J. Biol. Chem. 266, 4484–4488 (1991).
Zhu, L.A. & Weller, S.K. The UL5 gene of herpes simplex virus type 1: Isolation of a lacZ insertion mutant and association of the UL5 gene product with other members of the helicase-primase complex. J. Virol 66, 1458–1468 (1992).
Selway, C.N. & Terrett, N.K. Parallel-compound synthesis: Methodology for accelerating drug discovery. Bioorganic Med. Chem. 4, 645–654 (1996).
Spector, F.C., Liang, H., Giordano, H., Sivaraja, M. & Peterson, M.G. Inhibition of herpes simplex virus replication by a 2-amino thiazole via interactions with the helicase component of the UL5-UL8-UL52 complex. J. Virol. 72, 6979–6987 (1998).
Shin, Y.K., Cai, G.-Y., Weinberg, A., Leary, J.J. & Levin, M.J. Frequency of acyclovir-resitant herpes simplex virus in clinical specimens and laboratory isolates. J. Clin. Microbiol. 39, 913–917 (2001).
Thackray, A.M. & Field, H.J. Differential effects of famciclovir and valacyclovir on the pathogenesis of herpes simplex virus in a murine infection model including reactivation from latency. J. Infect. Dis. 173, 291–299 (1996).
Kern, E.R. Acyclovir treatment of experimental genital herpes simplex virus infections. Am. J. Med. 73, 100–108 (1982).
Reichman, R.C. et al. Treatment of recurrent genital herpes simplex infections with oral acyclovir. J. Am. Med. Ass. 251, 2103–2107 (1984).
Spruance, S.L. et al. Treatment of recurrent herpes simplex labialis with oral. J. Infect. Dis. 161, 185–190 (1990).
Lawetz, C. & Liuzzi, M. The antiviral activity of the ribonucleotide reductase inhibitor BILD 1351 SE in combination with acyclovir against HSV type-1 in cell culture. Antiviral Res. 39, 35–46 (1998).
Duan, J. et al. Antiviral activity of a selective ribonucleotide reductase inhibitor against acyclovir-resistant herpes simplex virus type 1 in vivo. Antimicrob. Agents Chemother. 42, 1629–1635 (1998).
Liuzzi, M. et al. A potent peptidomimetic inhibitor of HSV ribonucleotide reductase with antiviral activity in vivo. Nature 372, 695–698 (1994).
Erlich, K.S. et al. Acyclovir-resistant herpes simplex virus infections in patients with the acquired immunodeficiency syndrome. N. Engl. J. Med. 320, 293–296 (1989).
Chatis, P.A. & Crumpacker, C.S. Resistance of herpesviruses to antiviral drugs. Antimicrob. Agents Chemother. 36, 1589–1595 (1992).
Langelier, Y., Dechamps, M. & Buttin, G. Analysis of dCMP deaminase and CDP reductase levels in hamster cells infected by herpes simplex virus. J. Virol. 26, 547–553 (1978).
Dodson, M.S., Crute, J.J., Bruckner, R.C. & Lehman, I.R. Overexpression and assembly of the herpes simplex virus type 1 helicase-primase in insect cells. J. Biol. Chem. 264, 20835–20838 (1989).
Dracheva, S., Koonin, E.V. & Crute, J.J. Identification of the primase active site of the herpes simplex virus type 1 helicase-primase. J. Biol. Chem. 270, 14148–14153 (1995).
Crute, J.J., Mocarski, E.S. & Lehman, I.R. A DNA helicase induced by herpes simplex virus type 1. Nucleic Acids Res. 16, 6585–6596 (1988).
Lanzetta, P.A., Alvarez, L.J., Reinbach, P.S. & Candia, O.A. An improved assay for nanomole amounts of inorganic phosphate. Anal. Biochem. 100, 95–97 (1979).
Tenney, D.J., Sheaffer, A.K., Hurlburt, W.W., Bifano, M. & Hamatake R.K. Sequence-dependent primer synthesis by the herpes simplex virus helicase-primase complex. J. Biol. Chem. 270, 9129–9136 (1995).
Lakowicz, J.R. Principles of Fluorescence Spectroscopy. 145–147 (Plenum Press, New York, 1983).
Bolger, G.T. et al. Cutaneously applied acyclovir acts systemically in the treatment of herpetic infection in the hairless mouse. Antiviral Res. 35, 157–165 (1997).
Morahan, P.S., Breinig, M.C., McGeorge, M.B. Immune responses to vaginal or systemic infection of BALB/c mice with herpes simplex virus type 2. J. Immunol. 119, 2030–2036 (1977).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Crute, J., Grygon, C., Hargrave, K. et al. Herpes simplex virus helicase-primase inhibitors are active in animal models of human disease. Nat Med 8, 386–391 (2002). https://doi.org/10.1038/nm0402-386
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/nm0402-386
This article is cited by
-
Targeting herpes simplex virus with CRISPR–Cas9 cures herpetic stromal keratitis in mice
Nature Biotechnology (2021)
-
Repurposing potential of posaconazole and grazoprevir as inhibitors of SARS-CoV-2 helicase
Scientific Reports (2021)
-
The Influence of Hepatic and Renal Impairment on the Pharmacokinetics of a Treatment for Herpes Zoster, Amenamevir (ASP2151): Phase 1, Open-Label, Single-Dose, Parallel-Group Studies
Advances in Therapy (2017)
-
Pharmacokinetics and Safety of Amenamevir in Healthy Subjects: Analysis of Four Randomized Phase 1 Studies
Advances in Therapy (2017)
-
Update on New Antivirals Under Development for the Treatment of Double-Stranded DNA Virus Infections
Clinical Pharmacology & Therapeutics (2010)